iShares Nasdaq Biotechnology ETF (IBB)
121.89
-0.46 -0.38%
NASDAQ
Jan 17, 20:00
Delayed 2m
USD
Key Stats
| Expense Ratio | 0.47% |
| Total Assets Under Management | 7.651B |
| Share Class Assets Under Management | 7.651B |
| 30-Day Average Daily Volume | 2.583M |
| Net Asset Value | 121.83 |
| Discount or Premium to NAV | 0.05% |
| Turnover Ratio | 18.00% |
| 1 Year Fund Level Flows | -1.694B |
View All IBB News
News
-
WireHeadlineTime (ET)
-
MT Newswires01/17 08:47
-
MT Newswires01/16 08:55
-
Yahoo01/15 09:27
-
MT Newswires01/15 08:22
-
MT Newswires01/14 08:28
-
MT Newswires01/13 08:02
-
Yahoo01/13 07:58
-
Yahoo01/10 08:52
-
MT Newswires01/10 08:21
-
Yahoo01/09 16:01
Performance & Returns
| Total Return (Price) | Total Return (NAV) | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|---|
| 1M | 0.74% | 0.69% | 3.36% | 90 |
| 3M | 18.36% | 18.22% | 18.51% | 42 |
| 6M | 15.58% | 15.46% | 14.67% | 37 |
| YTD | 1.15% | 1.05% | 2.52% | 88 |
| 1Y | 11.23% | 11.14% | 20.23% | 92 |
| 3Y | 10.28% | 10.24% | 15.66% | 82 |
| 5Y | 3.03% | 3.02% | 8.59% | 91 |
| 10Y | 16.07% | 16.06% | 14.80% | 27 |
| 15Y | 11.59% | 11.59% | 11.31% | 46 |
| 20Y | -- | -- | 9.78% | -- |
Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | 0.07% | 0.07% | 0.00% |
| Stock | 99.93% | 99.93% | 0.00% |
| Bond | 0.00% | 0.00% | 0.00% |
| Convertible | 0.00% | 0.00% | 0.00% |
| Preferred | 0.00% | 0.00% | 0.00% |
| Other | 0.00% | 0.00% | 0.00% |
Region Exposure
| Americas | 93.20% |
| North America | 93.20% |
| Latin America | 0.00% |
| Greater Europe | 5.03% |
| United Kingdom | 1.99% |
| Europe Developed | 2.91% |
| Europe Emerging | 0.00% |
| Africa/Middle East | 0.13% |
| Greater Asia | 1.77% |
| Japan | 0.00% |
| Australasia | 0.00% |
| Asia Developed | 0.18% |
| Asia Emerging | 1.59% |
| Market Classification | |
| % Developed Markets | 98.41% |
| % Emerging Markets | 1.59% |
Stock Sector Exposure
| Basic Materials | 0.04% |
| Communication Services | 0.00% |
| Consumer Cyclical | 0.00% |
| Consumer Defensive | 0.00% |
| Energy | 0.00% |
| Financial Services | 0.00% |
| Healthcare | 99.96% |
| Industrials | 0.00% |
| Real Estate | 0.00% |
| Technology | 0.00% |
| Utilities | 0.00% |
Stock Market Capitalization
| Giant | 9.37% |
| Large | 35.25% |
| Medium | 29.69% |
| Small | 21.07% |
| Micro | 4.61% |
Stock Style Exposure
| Large Cap Value | 17.03% |
| Large Cap Blend | 18.49% |
| Large Cap Growth | 14.78% |
| Mid Cap Value | 1.57% |
| Mid Cap Blend | 4.43% |
| Mid Cap Growth | 22.75% |
| Small Cap Value | 1.59% |
| Small Cap Blend | 6.11% |
| Small Cap Growth | 13.27% |
View More Holdings
As of Jan. 16, 2020
Top 10 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| AMGN | Amgen Inc | 8.08% | 241.49 | +0.41% |
| GILD | Gilead Sciences Inc | 7.41% | 62.98 | -0.35% |
| VRTX | Vertex Pharmaceuticals Inc | 7.18% | 235.83 | +0.14% |
| BIIB | Biogen Inc | 6.12% | 285.50 | -0.22% |
| ILMN | Illumina Inc | 5.68% | 324.72 | -0.38% |
| REGN | Regeneron Pharmaceuticals Inc | 4.12% | 385.94 | +0.10% |
| ALXN | Alexion Pharmaceuticals Inc | 2.99% | 113.27 | +0.68% |
| SGEN | Seattle Genetics Inc | 2.22% | 109.00 | +1.24% |
| INCY | Incyte Corp | 2.09% | 80.50 | -0.15% |
| BMRN | Biomarin Pharmaceutical Inc | 1.92% | 88.27 | -0.96% |
Advertisement
Basic Info
| Investment Strategy | |
|---|---|
| The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified. | |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | iShares |
| Reports | |
| One Page Report | Download |
Manager Info
| Name | Tenure |
|---|---|
| Alan Mason | 3.71 yrs |
| Amy Whitelaw | 1.42 yrs |
| Greg Savage | 12.01 yrs |
| Jennifer Hsui | 7.42 yrs |
| Rachel Aguirre | 1.42 yrs |
Net Fund Flows
| 1M | -545.61M |
| 3M | -583.22M |
| 6M | -845.81M |
| YTD | -1.694B |
| 1Y | -1.694B |
| 3Y | -2.711B |
| 5Y | -788.62M |
| 10Y | 865.55M |
Risk Info
| Beta (5Y) | 1.425 |
| Max Drawdown (All) | 62.85% |
| Historical Sharpe Ratio (10Y) | 0.8592 |
| Historical Sortino (All) | 0.472 |
| 30-Day Rolling Volatility | 12.34% |
| Daily Value at Risk (VaR) 1% (All) | 4.71% |
| Monthly Value at Risk (VaR) 1% (All) | 19.15% |
Fundamentals
| Dividend Yield TTM (1-17-20) | 0.17% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Weighted Average PE Ratio | 20.89 |
| Weighted Average Price to Sales Ratio | 6.283 |
| Weighted Average Price to Book Ratio | 4.924 |
| Weighted Median ROE | 5.57% |
| Weighted Median ROA | -4.03% |
| Forecasted Dividend Yield | 0.64% |
| Forecasted PE Ratio | 15.14 |
| Forecasted Price to Sales Ratio | 4.422 |
| Forecasted Price to Book Ratio | 3.823 |
| Number of Holdings | 220 |
Growth Estimates
| Forecasted 5 Yr Earnings Growth | 9.91% |
| Forecasted Book Value Growth | 8.87% |
| Forecasted Cash Flow Growth | -0.40% |
| Forecasted Earnings Growth | 15.36% |
| Forecasted Revenue Growth | 8.21% |
Attributes
| Key Dates | |
|---|---|
| Inception Date | 2/5/2001 |
| Termination Date | |
| Last Annual Report Date | 3/31/2019 |
| Last Prospectus Date | 8/1/2019 |
| Attributes | |
| Exchange Traded Share | Yes |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Fixed Distribution Fund | No |
| High-Net Worth Individual Fund | No |
| Index Fund | Yes |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | Yes |
| Socially Responsible Fund | No |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
Advertisement
